Reduced post-transplant performance status because of infectious complications is still a problem following autologous peripheral blood stem cell transplantation (aPBSCT). In this study, a tandem transplantation scheme for 15 patients with breast cancer including etoposide (1500 mg/m 2 ), ifosfamide (12 g/m 2
) as conditioning regimens, followed by aPBSCT, was used to evaluate the potential clinical benefit of the additional retransfusion of low numbers of ex vivo expanded committed myeloid postprogenitor cells (PPCs) (median 408 Â 103 CFU-c/kg BW, range 0. following the second transplantation. Following a 7+2 days expansion (using recombinant human SCF, IL1b, IL-3, IL-6 + G-CSF), CFU-c generated from CD34-positive cells from leukapheresis products could be expanded by a median factor of 153 (range 5-434). Flow cytometric analysis and morphology of CFUs have shown a nearly exclusive expansion and differentiation of committed myeloid progenitor cells and a significant reduction of CD34-positive cells. In an intra-and interindividual comparison it could be shown that the retransfusion of committed myeloid postprogenitor cells significantly accelerates myeloid recovery. Although retransfusion of PPCs fails to abrogate severe neutropenia following aPBSCT, it significantly ameliorates infectious complications and shortens the duration of hospital stay. Bone Marrow Transplantation (2003) 32, 299-305. doi:10.1038/sj.bmt.1704126 Keywords: autologous transplantation; hematopoietic recovery; ex vivo expansion; myeloid progenetors; neutropenic fever
The neutropenic period after high-dose chemotherapy (HD-CT) and autologous transplantation may be associated with a high rate of fever and systemic infections. 1, 2 The rate of infectious complications increases with the duration of neutropenia. 3 There are several possibilities to shorten the pancytopenic period after autologous transplantation. The use of mobilized peripheral blood stem cells (PBSC) instead of bone marrow (BM) stem cells or increasing the dose of transplanted CD34+ cell dose accelerates the post transplant hemopoietic recovery and improves patients performance after autologous transplantation. 3 However, enhancing the number of CD34+ cells in the transplant over a threshold of 5 Â 10 6 /kg body weight (BW) leads to no further acceleration of neutrophil recovery. 4, 5 The additional application of hemopoietic growth factors or growth factor combinations during the post-transplant period has only limited effect on the duration of neutropenia and did not abrogate neutropenic fever in randomized trials. 6 One possible way to overcome the consequences of prolonged neutropenia could be the ex vivo expansion and myeloid differentiation of hematopoietic stem and progenitor cells. Up to now most study groups focused mainly on the expansion of primitive hematopoietic progenitor cells with long-term repopulating ability to abrogate neutropenic fever. 7, 8 Furthermore, all studies to date have compared the time to neutrophil recovery with historical controls.
In the present study, we have sought to determine if ex vivo expanded postprogenitor cells (PPCs) shorten the neutropenic period, and improve the clinical outcome of patients after autologous tandem transplantation. The double transplantation concept allows for intraindividual comparison of the duration of neutropenia, as well as the number of febrile episodes between the first and the second chemotherapy cycle. We were able to show that the transfusion of ex vivo expanded myeloid PPCs with unipotent differentiation capacity and distinct immunophenotype significantly reduces the duration of neutropenia. It also improves the clinical outcome after HD-CT compared to autologous transplantation without ex vivo expanded cells. Only relatively small numbers of CD34+ cells were required for the generation of sufficient numbers of CFU-G and CFU-M to almost abrogate post-transplant neutropenic fever after HD-CT.
Materials and methods

Patients
In all, 35 consecutive patients with metastatic breast cancer (n ¼ 34) or non-small-cell lung cancer (n ¼ 1) were included in the study after giving informed consent. The first 20 patients received no ex vivo expanded myeloid progenitor cells (control group), the following 15 patients received ex vivo expanded cells. The evaluation of the patients' pretreatment therapies indicated that 21 of 35 had received prior radiotherapy and/or chemotherapy. Pretreatment characteristics in the control and study group were well balanced. Pretreatment of the patients receiving no additional cells or ex vivo expanded myeloid progenitor cells was as follows (control group/study group): radiotherapy (n ¼ 5/3), radiochemotherapy (n ¼ 3/3) and one chemotherapy schedule (n ¼ 6/4), two schedules (n ¼ 4/2), no prior chemotherapy (n ¼ 2/3). All patients with breast cancer were at stage IV at primary diagnosis (n ¼ 9) or relapse (n ¼ 25) and had high-risk profiles according to the Possinger Score. 9 The median age was 44 years (35-54 years). Only patients with normal vital organ function and a Karnofsky-Index 480% were eligible for the study. Patients with histologic evidence of tumor cells in the BM were excluded. All patients gave written informed consent before study enrollment. The study was approved by the institutional review board as well as by local governmental authorities. ). This is a regimen with broad activity against a variety of cancers. 10 Starting 4 days after chemotherapy, patients received filgrastim (granulocyte colony-stimulating factor (G-CSF), Amgen, Munich, Germany) at a dose of 10 mg/kg BW subcutaneously to enhance the mobilization of PBSC.
Induction chemotherapy and stem cell mobilization
PBSCs were collected by leukapheresis starting at peripheral blood CD34 counts of 10 ) CD34+ cells/kg of BW were collected and cryopreserved. The leukapheresis product was pooled and divided into at least four portions: two identical aliquots for transplantation, one back-up and one aliquot for ex vivo expansion. Thus, identical cell numbers could be reinfused following conditioning one and two.
Enrichment for CD34+ cells
Cells from leukapheresis products were thawed and enriched for CD34+ cells using the CeprateSC cell concentrator (CellPro, Bothell, Washington, USA), following the instructions of the manufacturer. Briefly, the cells were incubated with biotinylated anti-CD34 monoclonal antibody (QBEND10, CellPro) for 25 min at room temperature. After washing the cell suspension, the cells were loaded on the avidin column. Adherent cells were removed automatically from the column, collected in PBS and used immediately for expansion.
Ex vivo myeloid progenitor cell expansion
For ex vivo expansion, CD34+ enriched mononuclear cells (MNCs) from leukapheresis products were seeded in 100 ml Teflon bags (Baxter, Munich, Germany) at a median cell concentration of 4.1 Â 10 4 /ml (range 2.5-9.3 Â 10 4 MNC/ ml). These cells were cultured for 9 days in RPMI 1640 medium (Seromed-Biochrom, Berlin, Germany), 2% autologous plasma, recombinant human stem cell factor (SCF: 10 ng/ml), recombinant human interleukin-1b (IL-1b: 10 ng/ml), human recombinant interleukin-3 (IL-3: 10 ng/ ml) and human recombinant interleukin-6 (IL-6: 10 ng/ml), as described by Haylock. 11 All cytokines were purchased from R&D Systems Europe, Abingdon, UK. After 7 days, 10 ng/ml recombinant human G-CSF (Amgen, Munich, Germany) was added.
At day 9, the nonadherent cells were collected from the bags, washed twice in 0.9% saline, and resuspended in 250 ml 0.9% saline supplemented with human albumin (Cutter, Cologne, Germany) for reinfusion. All ex vivo expanded cells were additionally screened for bacterial or fungal contamination and endotoxin.
Tandem HD-CT and transplantation
At 3 weeks after mobilization chemotherapy HD-CT was administered ( Figure 1 ). This consisted of etoposide (total dose 1500 mg/m 2 ) ifosfamide (total dose 12 g/m 2 ) and carboplatin (total dose 1500 mg/m 2 ) on day À4 to À1 (VIC1). A median number of 3.5 Â 10 6 CD34+ cells/kg (range 2.6-5.1 Â 10 6 ) were transplanted on day 0. All patients (n ¼ 35) achieved at least a partial remission following VIC1, which was a prerequisite for starting a second cycle of HD-CT.
An identical cycle of HD-CT (VIC2) was given 3.8 (mean) weeks later (range 3.1-4.8 weeks). For hematopoietic rescue, the same number of CD34+ cells as in the preceding cycle (VIC1) was transfused on day 0. Of the 35 consecutive patients, 15 received in addition ex vivo expanded myeloid differentiated PPCs on day +2 (Table 1) , 20 patients (control group) received no PPCs following VIC2.
All patients received selective decontamination with ciprofloxacin 2 Â 750 mg p.o., starting with chemotherapy, and G-CSF (Neupogen s 300 mg daily) from day +4 until /l. The same standard supportive regimens were used for each transplantation. Blood count and levels of C-reactive protein (CRP) were monitored daily.
Analysis of progenitor cells
Colony assays were performed on day 0 of ex vivo expansion and on day 9 as described. 12 Clonogenic assays were performed in methylcellulose-containing medium supplemented with 30% FCS and the following recombinant human growth factors: 10 ng/ml granulocyte-macrophage-colony stimulating factor (GM-CSF), 3 U/ml erythropoetin (Epo), 50 ng/ml SCF and 10 ng/ml IL-3 (Methocult GF, Stem Cell Technologies, Vancouver, CA, USA). Myeloid colony-forming cells (CFC-GM, CFC-G, CFC-M), erythroid colony-forming cells (BFU-E and CFU-E) and mixed erythroid-myeloid colony forming cells (Mixed-CFC) were counted. They were scored in triplicate cultures as described previously 13 using a dissection microscope (Leica, Wetzlar, Germany) at Â 40 magnification. As a result of the predominance of CFU-G and CFU-M after expansion, the number of myeloid and erythroid CFC was added and the total number of colony-forming cells (CFU-c) was calculated irrespective of the lineage.
The CD34-enriched cell population before expansion and the cells after 9 days ex vivo expansion were analyzed by flow cytometry using a FACScan (Becton-Dickinson, Heidelberg, Germany) with monoclonal antibodies against the following surface markers: CD45, CD3, CD4, CD5, CD8, CD34, CD56 (all from Becton-Dickinson, Heidelberg, Germany), CD14, CD16, HLA-DR (from Immunotech, Marseille, France), CD10, CD45RA (Coulter, Unterschleissheim, Germany), CD33, CD38, CD64 (from Caltag, Hamburg, Germany), CD19 (Sigma, Taufkirchen, Germany) and CD71 (Ortho, Raritan, NJ, USA). The percentage of CD34+ cells in the expanded cell population was determined following the ISHAGE guidelines regarding use of SSC and CD45 expression levels. 14 The surface markers were chosen according to the following aspects: CD45 was used as panleukocyte marker and gating parameter, and CD34 as stem cell marker. CD71 is expressed on erythroid and monocytic cells, but also indicates early proliferating hematopoietic cells (coexpression of CD45). HLA-DR is found on progenitor cells, CD14 on monocytic cells. CD4-positive/CD3-negative cells show monocytic or promyelocytic differentiation. The surface markers CD90 and CD38 are expressed on early progenitor cells and are lost during differentiation. 15, 16 Statistics and analysis of engraftment correlates Primary end points of the study were safety of infusion of cultured cells and time to neutrophil recovery after transplantation. Further end points were number of febrile days during neutropenia, duration of hospital stay, use of antibiotics in neutropenia and levels of CRP. The significance of comparison between VIC1 and VIC2 as well as between test and control group was determined at 95% confidence interval using a two-tailed Student's t-test.
Time to neutrophil recovery was defined as time interval between day 0 (day of transplantation) and the first day with WBC 41 Â 10 9 /l. The discharge criteria were WBC 41 Â 10 9 /l and no fever and no other disorders that had to be treated as inpatient.
Fever was defined as temperature X38.01C on two consecutive days or fever X38.51C on 1 day. In those cases, empirical or site-specific antimicrobial chemotherapy was administered. Neutropenia was defined as neutrophil count o0.5 Â 10 9 /l. Antipyretic drugs were administered in cases with fever 439.01C.
During retransfusion of PBSC or ex vivo expanded cells, ECG, blood pressure and blood oxygenation were monitored. The temperature was measured twice within 2 h. Additionally, the patients were monitored clinically.
Results
Ex vivo expansion
Aliquots of the leukapheresis product of 15 patients were used for CD34 enrichment as described in the Materials and method section. The percentage of CD34+ cells in the enriched fraction was 75.877.2%. These cells were seeded immediately after enrichment into gas-permeable teflon bags. The median number of retransfused ex vivo expanded MNCs was 44 Â ). Thus, only half the number of CFU-c was reinfused after ex vivo expansion on day 2 than on day 0 with the unmanipulated transplant. However, CFU composition was significantly different. The effect of the cytokine cocktail in inducing myeloid differentiation is demonstrated by the virtual absence of primitive CFU-GM (up to 3.9% of CFU-c) and a predominance of small neutrophil (CFU-G) and macrophage (CFU-M) colonies with low /kg BW CD34+ (range 0.31-3.67 Â 10 6 /kg BW) cells during the 9-day culture period. However, the composition of the CD34+ progenitor compartment changed fundamentally during ex vivo expansion. Almost no primitive progenitor cells, as included in the CD34+CD90+, CD34+CD38À or CD34+HLA-DRÀ subpopulation, were detectable in the expanded cell population (Figure 2b) . Most of the CD34+ cells expressed CD38 or HLA-DR, indicating that almost all CD34+ cells after ex vivo expansion were committed progenitor cells. Also, a considerable proportion of the CD34+ cells expressed lineage markers like CD33 (31.7%719.5%), CD45RA (38.3%730.7%) or high levels of CD71 (32.1%77.2%).
Safety and clinical efficacy
The ability of ex vivo expanded and myeloid differentiated PPCs to accelerate myeloid reconstitution after a second cycle of HD-CT (VIC 2) within a tandem-transplantation concept was tested in 15 consecutive patients. The remaining 20 patients did not receive any expanded stem cell fraction (control group).
Independent of the pretreatment in all 35 patients sufficient cell numbers could be collected for tandem transplantations, ex vivo expansion and back-up. A median of 9.8 Â 10 6 (range 7.8 Â 10 6 -13.6 Â 10 6 ) CD34+ cells per kg of body weight (kg BW) were collected and cryopreserved.
The median total volume of cell suspension used for ex vivo expansion was 543 ml (range 234-1118 ml). The administration of a median of 2.8 Â 10 9 ex vivo expanded PPCs (range 1.2-5.3 Â 10 9 ) suspended in an albumincontaining saline solution was not associated with any allergic side effects, hypotension or cardiac events. It was therefore well tolerated by the patients.
Quality control of the ex vivo expanded cell suspension for fungal, bacterial contamination or endotoxin before retransfusion resulted in negative results. Hematopoietic recovery was significantly accelerated following VIC2+PPC. All patients had neutropenia (neutrophil count o0.5 Â 10 9 /l) following VIC1 or 2. For patients receiving ex vivo expanded cells after VIC2, the median Starting from day 7 (Figure 3) , significantly (Po0.0002) higher neutrophil counts during hematopoietic recovery could be observed in patients treated with expanded PPCs following VIC 2 compared with VIC 1. The additional application of ex vivo expanded committed myeloid PPC had no significant influence on thrombocyte recovery or long-term hematopoietic reconstitution at 6 and 12 months (leukocytes 44/nl, Hb412 g/dl, thrombocytes 4100/nl). The acceleration of leukocyte recovery via the retransfusion of low numbers of ex vivo expanded myeloid differentiated PPCs was associated with significantly improved clinical outcomes in terms of inflammatory serum parameters, incidence of neutropenic fever, days on antibiotics and time of hospitalization ( Figure 3 ). CRP levels in serum on day 9 were significantly (Po0.0001) lower following VIC2+PPC vs VIC1 (Figure 3a) , whereas CRP levels on day 9 within the control group achieved high levels and did not significantly differ between VIC1 and VIC2 (P ¼ 0.34).
Low CRP levels following VIC2+PPC were accompanied with a significantly lower number of febrile episodes compared to VIC1 (P ¼ 0.0054) (Figure 3c ). Within the control group a similar incidence of febrile episodes in VIC1 or VIC2 could be observed (P ¼ 0.81).
The consequence of a lower incidence of febrile episodes was a reduced consumption of interventionally applied antibiotics following VIC2+PPC. Both the number of days on antibiotics in patients with febrile episodes and the number of patients who needed antibiotics were significantly lower (Table 2) .
Owing to the improved performance status of the patients during hematopoietic recovery, the time of hospitalization (Table 2 ) was significantly shortened following VIC2+PPC (P ¼ 0.008).
No cytopenia or any other defect in the long-term hematopoiesis was found 1 and 2 years after transplantation in patients who received expanded cells compared to control patients.
The retransfusion of low numbers of committed myeloid PPCs does accelerate hematopoietic reconstitution after autologous PBSCT. As this study demonstrates, this may improve post-transplant outcome.
Discussion
This study documents for the first time in an intraindividual comparison that the retransfusion of ex vivo expanded myeloid PPCs along with myeloid committed progenitor cells (CFU-G and CFU-M) significantly reduces infectious complications, the need for antibiotic therapy and shortens the time of hospitalization following HD-CT. The improvement in patients' post-transplant outcome may be attributable to a more rapid engraftment of myeloid cells after retransfusion of ex vivo expanded myeloid committed cells. postprogenitor cells per kg BW. In another study reported by Reiffers, 7 a strong reduction of neutropenic days after reinfusion of ex vivo expanded cells was seen. In this study more than three times as many nucleated cells and more than six times as many CD34+ cells as in our study were infused after ex vivo expansion.
Furthermore, the number of committed myeloid postprogenitor cells necessary to substantially reduce febrile episodes is much lower than a recently calculated number of PPCs necessary to completely abrogate neutropenia. 19 We therefore show that the additional transplantation of ex vivo generated PPCs and highly committed myeloid progenitors (like CFU-G and CFU-M) is similarly effective to abrogate neutropenic fever as the retransfusion of high numbers of more primitive progenitor cells (like CFU-GM) generated ex vivo. 7, 16 Our ex vivo expansion protocol is able to maintain the number of CD34+ cells during the 9-day culture period. Although the number of CD34+ cells infused was almost identical to the number of CD34+ cells seeded, the proportion of primitive and committed hematopoietic progenitor cells changed. Whereas cells with a primitive immunophenotype (like CD34+CD90+ or CD34+ CD38À) were detectable in the leukapheresis product before expansion, no such cells were found after ex vivo expansion. The same applied to the CFC after ex vivo expansion. The majority of CFC in the leukapheresis product were CFC-GM or BFU-E. In contrast, only small unipotent colonies (mainly CFC-G and CFC-M) were detectable after ex vivo expansion and no CFC of the erythroid lineage. Both results indicate that in our study no stem cells or primitive progenitor cells were expanded.
The cytokine cocktail (IL-1, IL-3, IL-6 and SCF) used for expansion derives from studies done by Haylock et al.
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Initial experiments in our laboratory have shown that the addition of G-CSF leads to a high degree of PMNC amplification (data not shown). G-CSF was therefore added near the end of the culture period, and then only for 2 days. Interestingly, this cytokine cocktail yielded mainly PPCs and committed myeloid CFC of limited proliferative capacity. In contrast to other studies 7,18 using SCF, MGDF and G-CSF as cytokines for ex vivo expansion we found almost no primitive progenitors (like CFU-GM) or stem cells. The impact of other cytokines, such as thrombopoietin (TPO) for lineage-specific myeloid expansion remains unknown, especially given that excessive retransfusion of CFU-GM is not necessary to abrogate neutropenic fever.
The expansion technique used in this study can be routinely applied and easily handled. CD34+ cells enriched from leukapheresis products can efficiently be expanded and differentiated into large numbers of myeloid PPCs. In our hands it was not necessary to collect many more CD34+ cells during leukapheresis than normal. Therefore, the use of expanded myeloid PPC may be recommended, especially in patients who have preceding infectious complications due to their underlying disease or prior chemotherapy. Table 2 Number of days on antibiotics and time of hospitalization from day 0 (transplantation) 
